nach oben

Current Obstetrics and Gynecology Reports

Erschienen in:

26.01.2023 | REVIEW

Fetal Risks and Morbidity in Pregnant Individuals with Obesity

verfasst von: Tiffany Wang, Maisa Feghali

Erschienen in: Current Obstetrics and Gynecology Reports | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To provide an up-to-date summary on the fetal risks associated with maternal obesity, specifically the risks of fetal anomalies, abnormal fetal growth, and stillbirth.

Recent Findings

With the emerging data on fetal outcomes in individuals with the highest class of obesity, there is growing evidence that for many fetal adverse outcomes, there is a direct relationship between increasing maternal obesity class and the severity of the fetal outcome.

Summary

Maternal obesity is associated with an increased risk of various fetal anomalies including fetal congenital cardiac disease, although there is a decreased risk of fetal gastroschisis. There is also an increased risk of both fetal macrosomia and fetal growth restriction in individuals with obesity. There is an approximately twofold increase in the risk of stillbirth in individuals with obesity. For many of these fetal risks, there is dose-response relationship between obesity class and severity of the fetal outcome. Fetal aneuploidy and sonographic screening strategies can be more challenging in individuals with obesity, which may contribute to under-detection and increased neonatal morbidity. At this time, prevention of these fetal risks is focused on prenatal weight optimization.

Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i–xii, 1–253.

Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief. 2020;1–8.

Institute of Medicine. Weight gain during pregnancy: reexamining the guidelines. Washington, DC: National Academies Press. 2009.

American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Obstetrics, 2021 Obesity in pregnancy: ACOG practice bulletin, number 230 Obstet Gynecol. 137:e128–e144.

Waller DK, Shaw GM, Rasmussen SA, Hobbs CA, Canfield MA, Siega-Riz A-M, Gallaway MS, Correa A. National Birth Defects Prevention Study. Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med. 2007;161:745–50.CrossRef

Racusin D, Stevens B, Campbell G, Aagaard KM. Obesity and the risk and detection of fetal malformations. Semin Perinatol. 2012;36:213–21.PubMedPubMedCentralCrossRef

Stothard KJ, Tennant PWG, Bell R, Rankin J. Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. JAMA. 2009;301:636–50.PubMedCrossRef

•• Persson M, Razaz N, Edstedt Bonamy A-K, Villamor E, Cnattingius S. Maternal overweight and obesity and risk of congenital heart defects. J Am Coll Cardiol. 2019;73:44–53. This is the largest recent cohort study of the risks of fetal congenital heart disease in pregnant individuals with obesity. This study demonstrated a dose-response relationship between BMI class and various fetal congenital heart anomalies.PubMedCrossRef

Helle E, Priest JR. Maternal obesity and diabetes mellitus as risk factors for congenital heart disease in the offspring. J Am Heart Assoc. 2020;9: e011541.PubMedPubMedCentralCrossRef

10.

Correa A, Marcinkevage J. Prepregnancy obesity and the risk of birth defects: an update. Nutr Rev. 2013;71(Suppl 1):S68-77.PubMedCrossRef

11.

Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295–300.PubMedPubMedCentral

12.

•• Hopkins MK, Koelper N, Caldwell S, Dyr B, Dugoff L. Obesity and no call results: optimal timing of cell-free DNA testing and redraw. Am J Obstet Gynecol. 2021;225:417.e1-417.e10. This retrospective cohort study demonstrated a higher prevalence of no-call cell-free fetal DNA screening results in individuals with obesity, mostly due to low fetal fraction, highlighting challenges in aneuploidy screening in this higher-risk population.PubMedCrossRef

13.

Rose NC. Genetic screening and the obese gravida. Clin Obstet Gynecol. 2016;59:140–7.PubMedCrossRef

14.

Thornburg LL, Mulconry M, Post A, Carpenter A, Grace D, Pressman EK. Fetal nuchal translucency thickness evaluation in the overweight and obese gravida. Ultrasound Obstet Gynecol. 2009;33:665–9.PubMedCrossRef

15.

Hui L, Bianchi DW. Fetal fraction and noninvasive prenatal testing: what clinicians need to know. Prenat Diagn. 2020;40:155–63.PubMedCrossRef

16.

Hildebrand E, Gottvall T, Blomberg M. Maternal obesity and detection rate of fetal structural anomalies. Fetal Diagn Ther. 2013;33:246–51.PubMedCrossRef

17.

Eastwood K-A, Daly C, Hunter A, McCance D, Young I, Holmes V. The impact of maternal obesity on completion of fetal anomaly screening. J Perinat Med. 2017;45:1061–7.PubMedCrossRef

18.

Hunsley C, Farrell T. The influence of maternal body mass index on fetal anomaly screening. Eur J Obstet Gynecol Reprod Biol. 2014;182:181–4.PubMedCrossRef

19.

• Mei JY, Han CS. Ultrasound for the pregnant person with diabesity. Clin Obstet Gynecol. 2021;64:144–58. This review article highlights the various fetal sonographic findings associated with obesity and diabetes. A thorough review of the challenges, including proposed solutions, for optimizing image acquisition and quality in pregnant individuals with obesity is discussed.PubMedCrossRef

20.

AIUM practice parameter for the performance of fetal echocardiography. J Ultrasound Med. 2020;39:E5–E16.

21.

Bak GS, Shaffer BL, Madriago E, Allen A, Kelly B, Caughey AB, Pereira L. Impact of maternal obesity on fetal cardiac screening: which follow-up strategy is cost-effective? Ultrasound Obstet Gynecol. 2020;56:705–16.PubMedCrossRef

22.

Phatak M, Ramsay J. Impact of maternal obesity on procedure of mid-trimester anomaly scan. J Obstet Gynaecol. 2010;30:447–50.PubMedCrossRef

23.

Howell KR, Powell TL. Effects of maternal obesity on placental function and fetal development. Reproduction. 2017;153:R97–108.PubMedCrossRef

24.

Lewandowska M. Maternal obesity and risk of low birth weight, fetal growth restriction, and macrosomia: multiple analyses. Nutrients. 2021. https://doi.org/10.3390/nu13041213.CrossRefPubMedPubMedCentral

25.

• Zhang C, Hediger ML, Albert PS, et al. Association of maternal obesity with longitudinal ultrasonographic measures of fetal growth: findings from the NICHD fetal growth studies-singletons. JAMA Pediatr. 2018;172:24–31. This multi-center analysis identified various increased fetal biometric measurements in individuals with obesity starting from 21 weeks’ gestation through term delivery but, importantly, highlighted that these biometric differences became more pronounced particularly at and beyond 32 weeks’ gestation.PubMedCrossRef

26.

Tanaka K, Matsushima M, Izawa T, Furukawa S, Kobayashi Y, Iwashita M. Influence of maternal obesity on fetal growth at different periods of pregnancies with normal glucose tolerance. J Obstet Gynaecol Res. 2018;44:691–6.PubMedCrossRef

27.

O’Brien CM, Louise J, Deussen A, Grivell R, Dodd JM. The effect of maternal obesity on fetal biometry, body composition, and growth velocity. J Matern Fetal Neonatal Med. 2020;33:2216–26.PubMedCrossRef

28.

Tanner LD, Brock And C, Chauhan SP. Severity of fetal growth restriction stratified according to maternal obesity. J Matern Fetal Neonatal Med. 2022;35:1886–90.PubMedCrossRef

29.

Freeman DJ. Effects of maternal obesity on fetal growth and body composition: implications for programming and future health. Semin Fetal Neonatal Med. 2010;15:113–8.PubMedCrossRef

30.

Desai M, Ross MG. Fetal programming of adipose tissue: effects of intrauterine growth restriction and maternal obesity/high-fat diet. Semin Reprod Med. 2011;29:237–45.PubMedPubMedCentralCrossRef

31.

Weiss JL, Malone FD, Emig D, et al. Obesity, obstetric complications and cesarean delivery rate–a population-based screening study. Am J Obstet Gynecol. 2004;190:1091–7.PubMedCrossRef

32.

Chu SY, Callaghan WM, Kim SY, Schmid CH, Lau J, England LJ, Dietz PM. Maternal obesity and risk of gestational diabetes mellitus. Diabetes Care. 2007;30:2070–6.PubMedCrossRef

33.

Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19113342.CrossRefPubMedPubMedCentral

34.

Dunne F. Type 2 diabetes and pregnancy. Semin Fetal Neonatal Med. 2005;10:333–9.PubMedCrossRef

35.

Modanlou HD, Komatsu G, Dorchester W, Freeman RK, Bosu SK. Large-for-gestational-age neonates: anthropometric reasons for shoulder dystocia. Obstet Gynecol. 1982;60:417–23.PubMed

36.

Dude AM, Davis B, Delaney K, Yee LM. Identifying fetal growth disorders using ultrasound in obese nulliparous women. J Matern Fetal Neonatal Med. 2021;34:1768–73.PubMedCrossRef

37.

International Weight Management in Pregnancy (i-WIP) Collaborative Group. Effect of diet and physical activity based interventions in pregnancy on gestational weight gain and pregnancy outcomes: meta-analysis of individual participant data from randomised trials. BMJ. 2017;358: j3119.CrossRef

38.

Catalano PM. Reassessing strategies to improve pregnancy outcomes in overweight and obese women. Lancet Diabetes Endocrinol. 2019;7:2–3.PubMedCrossRef

39.

Management of stillbirth: obstetric care consensus No, 10. Obstet Gynecol. 2020;135:e110–e132.

40.

Flenady V, Koopmans L, Middleton P, et al. Major risk factors for stillbirth in high-income countries: a systematic review and meta-analysis. Lancet. 2011;377:1331–40.PubMedCrossRef

41.

Salihu HM. Maternal obesity and stillbirth. Semin Perinatol. 2011;35:340–4.PubMedCrossRef

42.

Ikedionwu CA, Dongarwar D, Yusuf KK, Ibrahimi S, Salinas-Miranda AA, Salihu HM. Pre-pregnancy maternal obesity, macrosomia, and risk of stillbirth: a population-based study. Eur J Obstet Gynecol Reprod Biol. 2020;252:1–6.PubMedCrossRef

43.

Mahomed K, Chan G, Norton M. Obesity and the risk of stillbirth - a reappraisal - a retrospective cohort study. Eur J Obstet Gynecol Reprod Biol. 2020;255:25–8.PubMedCrossRef

44.

Chu SY, Kim SY, Lau J, Schmid CH, Dietz PM, Callaghan WM, Curtis KM. Maternal obesity and risk of stillbirth: a metaanalysis. Am J Obstet Gynecol. 2007;197:223–8.PubMedCrossRef

45.

Woolner AMF, Bhattacharya S. Obesity and stillbirth. Best Pract Res Clin Obstet Gynaecol. 2015;29:415–26.PubMedCrossRef

46.

Harrison MS, Thorsten VR, Dudley DJ, et al. Stillbirth, inflammatory markers, and obesity: results from the stillbirth collaborative research network. Am J Perinatol. 2018;35:1071–8.PubMedPubMedCentralCrossRef

47.

Åmark H, Westgren M, Sirotkina M, Hulthén Varli I, Persson M, Papadogiannakis N. Maternal obesity and stillbirth at term; placental pathology-a case control study. PLoS ONE. 2021;16: e0250983.PubMedPubMedCentralCrossRef

48.

Bodnar LM, Parks WT, Perkins K, Pugh SJ, Platt RW, Feghali M, Florio K, Young O, Bernstein S, Simhan HN. Maternal prepregnancy obesity and cause-specific stillbirth. Am J Clin Nutr. 2015;102:858–64.PubMedPubMedCentralCrossRef

49.

Vasudevan C, Renfrew M, McGuire W. Fetal and perinatal consequences of maternal obesity. Arch Dis Child Fetal Neonatal Ed. 2011;96:F378–82.PubMedCrossRef

50.

American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice S for M-FM, 2021 Indications for outpatient antenatal fetal surveillance: ACOG committee opinion, number 828 Obstet Gynecol. 137:e177–e197.

Titel: Fetal Risks and Morbidity in Pregnant Individuals with Obesity
verfasst von: Tiffany Wang
Maisa Feghali
Publikationsdatum: 26.01.2023
Verlag: Springer US
Erschienen in: Current Obstetrics and Gynecology Reports / Ausgabe 1/2023
Elektronische ISSN: 2161-3303
DOI: https://doi.org/10.1007/s13669-023-00347-w

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen